SGT-710
Seborrheic Dermatitis
Phase 2Active
Key Facts
About Sol-Gel Technologies
Sol-Gel Technologies' mission is to develop and commercialize advanced topical dermatological therapies using its patented Sol-Gel microencapsulation platform. Its key achievement is the FDA approval and launch of TWYNEO® for acne vulgaris, marking its transition to a commercial entity. The company's strategy combines proprietary development of its pipeline with strategic out-licensing to established dermatology players for commercialization. With a pipeline of 15 candidates targeting acne, rosacea, psoriasis, and other conditions, Sol-Gel aims to build a portfolio of differentiated products in the growing medical dermatology market.
View full company profileTherapeutic Areas
Other Seborrheic Dermatitis Drugs
| Drug | Company | Phase |
|---|---|---|
| PEP Biologic™ | Intent Biologics | Unknown |
| Seborrheic Dermatitis Program | Sonoma Pharmaceuticals | Commercial |
| Topical Roflumilast Foam 0.3% (ZORYVE) | Arcutis Biotherapeutics | Approved |